Wedbush started coverage on shares of Zenas Biopharma (NASDAQ:ZBIO - Free Report) in a research note issued to investors on Thursday morning, MarketBeat.com reports. The firm issued an outperform rating and a $35.00 target price on the stock.
Separately, Guggenheim reiterated a "buy" rating and set a $45.00 target price on shares of Zenas Biopharma in a report on Wednesday, March 12th.
View Our Latest Stock Analysis on Zenas Biopharma
Zenas Biopharma Price Performance
Shares of Zenas Biopharma stock traded up $0.98 during trading on Thursday, hitting $9.31. The company's stock had a trading volume of 135,571 shares, compared to its average volume of 172,676. Zenas Biopharma has a 52 week low of $5.83 and a 52 week high of $26.25. The firm has a market cap of $389.15 million and a price-to-earnings ratio of -2.62.
Zenas Biopharma Company Profile
(
Get Free Report)
Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company. The firm is mainly engaged in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.
Featured Stories
Before you consider Zenas Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zenas Biopharma wasn't on the list.
While Zenas Biopharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
